O	0	9	Improving
O	10	13	the
O	14	21	quality
O	22	24	of
O	25	29	life
O	30	32	in
O	33	39	breast
O	40	46	cancer
O	47	56	survivors
O	57	59	at
O	60	64	risk
O	65	68	for
B-condition	69	79	lymphedema
O	79	80	.

O	81	88	Certain
O	89	99	treatments
O	100	108	increase
O	109	119	lymphedema
O	120	124	risk
O	125	127	in
O	128	134	breast
O	135	141	cancer
O	142	151	survivors
O	151	152	.

O	153	156	The
O	157	164	purpose
O	165	167	of
O	168	172	this
O	173	178	study
O	179	182	was
O	183	185	to
O	186	195	determine
O	196	203	whether
O	204	211	quality
O	212	214	of
O	215	219	life
O	220	228	improved
O	229	233	with
B-intervention	234	246	preoperative
I-intervention	247	255	teaching
I-intervention	256	258	by
I-intervention	259	260	a
I-intervention	261	271	lymphedema
I-intervention	272	278	expert
O	278	279	.

O	280	292	Preoperative
O	293	299	breast
O	300	306	cancer
O	307	315	patients
O	316	320	were
O	321	334	prospectively
O	335	345	randomized
O	346	350	into
O	351	363	intervention
O	364	369	group
O	370	371	1
O	372	374	or
B-control	375	382	control
I-control	383	388	group
O	389	390	2
O	390	391	.

O	392	397	Group
O	398	399	1
O	400	403	had
O	404	405	a
O	406	416	discussion
O	417	421	with
O	422	425	the
O	426	436	lymphedema
O	437	443	expert
O	444	447	and
O	448	450	at
O	451	452	6
O	453	459	months
O	459	460	,
O	461	463	in
O	464	472	addition
O	473	475	to
O	476	479	the
O	480	492	preoperative
O	493	501	surgical
O	502	512	discussion
O	513	516	and
O	517	527	literature
O	528	533	given
O	534	536	to
O	537	540	all
O	540	541	.

O	542	545	Arm
O	546	558	measurements
O	559	562	and
O	563	570	quality
O	571	573	of
O	574	578	life
O	579	589	evaluation
O	590	594	with
O	595	605	Functional
O	606	616	Assessment
O	617	619	of
O	620	626	Cancer
O	627	634	Therapy
O	634	635	-
O	635	641	Breast
O	642	648	Cancer
O	649	653	were
O	654	663	completed
O	664	678	preoperatively
O	679	682	and
O	683	685	at
O	686	695	intervals
O	696	699	for
O	700	702	up
O	703	705	to
O	706	707	3
O	708	713	years
O	713	714	.

O	715	725	Lymphedema
O	726	729	was
O	730	738	verified
O	739	743	with
O	744	745	a
O	746	748	10
O	748	749	%
O	750	758	increase
O	759	761	in
O	762	768	volume
O	769	771	or
O	772	785	circumference
O	785	786	.

O	787	797	Univariate
O	798	801	and
O	802	814	multivariate
O	815	823	analysis
O	824	828	were
O	829	838	performed
O	839	841	on
O	842	846	data
O	846	847	.

O	848	853	There
O	854	858	were
B-total-participants	859	862	119
O	863	872	evaluable
O	873	881	patients
O	882	886	with
O	887	889	no
O	890	901	differences
O	902	909	between
O	910	916	groups
O	917	918	1
O	919	922	and
O	923	924	2
O	924	925	.

O	926	929	The
B-outcome	930	934	rate
I-outcome	935	937	of
I-outcome	938	943	acute
I-outcome	944	954	lymphedema
O	955	958	was
B-iv-bin-percent	959	961	51
I-iv-bin-percent	961	962	.
I-iv-bin-percent	962	963	5
I-iv-bin-percent	963	964	%
O	965	966	(
B-iv-bin-abs	966	968	33
O	969	971	of
B-intervention-participants	972	974	64
O	974	975	)
O	976	979	for
O	980	985	group
O	986	987	1
O	988	991	and
B-cv-bin-percent	992	994	47
I-cv-bin-percent	994	995	.
I-cv-bin-percent	995	996	2
I-cv-bin-percent	996	997	%
O	998	999	(
B-cv-bin-abs	999	1001	26
O	1002	1004	of
B-control-participants	1005	1007	55
O	1007	1008	)
O	1009	1012	for
O	1013	1018	group
O	1019	1020	2
O	1020	1021	.

B-outcome	1022	1029	Chronic
I-outcome	1030	1040	lymphedema
O	1041	1050	presented
O	1051	1053	in
O	1054	1056	13
O	1057	1065	patients
O	1066	1067	(
B-iv-bin-percent	1067	1068	9
I-iv-bin-percent	1068	1069	.
I-iv-bin-percent	1069	1070	3
I-iv-bin-percent	1070	1071	%
O	1072	1077	group
O	1078	1079	1
O	1080	1083	and
B-cv-bin-percent	1084	1086	12
I-cv-bin-percent	1086	1087	.
I-cv-bin-percent	1087	1088	7
I-cv-bin-percent	1088	1089	%
O	1090	1095	group
O	1096	1097	2
O	1097	1098	)
O	1098	1099	.

B-outcome	1100	1110	Lymphedema
O	1111	1114	was
O	1115	1128	significantly
O	1129	1139	associated
O	1140	1144	with
O	1145	1151	number
O	1152	1154	of
O	1155	1160	lymph
O	1161	1166	nodes
O	1167	1175	resected
O	1176	1177	(
O	1177	1178	P
O	1179	1180	<
O	1181	1182	.
O	1182	1185	001
O	1185	1186	)
O	1186	1187	.

O	1188	1199	Significant
O	1200	1208	findings
O	1209	1211	in
O	1212	1215	the
O	1216	1226	Functional
O	1227	1237	Assessment
O	1238	1240	of
O	1241	1247	Cancer
O	1248	1255	Therapy
O	1255	1256	-
O	1256	1262	Breast
O	1263	1269	Cancer
O	1270	1274	were
O	1275	1277	at
O	1278	1279	6
O	1280	1286	months
O	1287	1290	for
O	1291	1294	all
O	1295	1298	and
O	1299	1304	after
O	1305	1314	diagnosis
O	1315	1317	in
O	1318	1328	lymphedema
O	1329	1337	positive
O	1338	1346	patients
O	1346	1347	.

O	1348	1358	Structured
O	1359	1369	lymphedema
O	1370	1378	teaching
O	1379	1382	can
O	1383	1387	help
O	1388	1390	to
O	1391	1398	improve
O	1399	1406	quality
O	1407	1409	of
O	1410	1414	life
O	1415	1417	in
O	1418	1428	lymphedema
O	1429	1437	patients
O	1437	1438	.
